RSLS - ReShape Lifesciences Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow

Income Statement

Annual
All numbers in thousands
Revenue12/31/201812/31/201712/31/201612/31/2015
Total Revenue606.71569.16786.66290.637
Cost of Revenue164.299333.276431.476123.684
Gross Profit442.411235.884355.184166.953
Operating Expenses
Research Development5,722.1175,441.1895,169.2868,141.323
Selling General and Administrative19,064.6822,848.92217,981.52519,892.424
Non Recurring----
Others----
Total Operating Expenses24,951.09628,623.38723,582.28728,157.431
Operating Income or Loss-24,344.386-28,054.227-22,795.627-27,866.794
Income from Continuing Operations
Total Other Income/Expenses Net-14,369.345-4,724.706-565.2172,368.047
Earnings Before Interest and Taxes-24,344.386-28,054.227-22,795.627-27,866.794
Interest Expense-12.378-2.808-4,104.003-939.182
Income Before Tax-38,713.731-32,778.933-23,360.844-25,498.747
Income Tax Expense-3,446.708-2,314.611--
Minority Interest----
Net Income From Continuing Ops-35,267.023-30,464.322-23,360.844-25,498.747
Non-recurring Events
Discontinued Operations-45,884.552-3,353.65-3,353.65-3,353.65
Extraordinary Items----
Effect Of Accounting Changes----
Other Items----
Net Income
Net Income-81,151.575-33,817.972-23,360.844-25,498.747
Preferred Stock And Other Adjustments----
Net Income Applicable To Common Shares-84,230.557-33,817.972-23,360.844-25,498.747